Form D · Other
Star Therapeutics LLC
South San Francisco, CA · CIK 0002088123
Offering snapshot reported Oct 6, 2025 · SEC filing
- Reported sold
- $125M Offering amount: $125M
- Investors reported
- 21 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 22, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 6, 2025 | Initial | $124,999,974 | No comparison | 21 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-559890
Source: Form D, filed Oct 6, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Michelle Carpenter | Executive |
| Matthew Fust | Director |
| Carl Gordon | Director |
| Jason Hafler | Director |
| Maha Katabi | Director |
| Amrit Nagpal | Director |
| Sandip Panicker | Executive |
| Gary Patou | Executive |
| Scott Robertson | Executive |
| Adam Rosenthal | Director, Executive |
| Beth Seidenberg | Director |
| Nancy Stagliano | Director |
Issuer details
Industry: Other (See others in industry)
Address:
201 Haskins Way, 5 Th Floor
South San Francisco, CA, 94080
South San Francisco, CA, 94080